Abbott stock after-hours at EUR 88.67: minus 0.11 percent
📉 Abbott stock closed at EUR 88.67 in after-hours trading on September 29, 2026, down 0.11 percent from the prior session's close of EUR 88.77.
🔬 New study data released on September 27 shows continuous glucose monitoring reduces mortality risk by 45% at 12 months for adults with Type 2 diabetes on basal insulin.
🏥 A separate French observational study involving over 253,000 people found a 47% reduction in hospitalizations for acute diabetes events among users of Abbott's Libre technology.
💰 The board declared a quarterly common dividend of 63 cents per share on September 17, payable November 16 to shareholders of record on October 15.
📊 Current market quotes show a bid of EUR 88.54 and an ask of EUR 88.80 following the Xetra close.
Bullish Signals
- Abbott announced data from studies showing continuous glucose monitoring is associated with a 45 percent lower risk of death at 12 months among nearly 28,000 adults with Type 2 diabetes using basal insulin.
- A separate French observational study involving more than 253,000 people found that hospitalizations for acute diabetes events fell 47 percent among users of Abbott's Libre technology on basal insulin.
- The company declared a quarterly common dividend of 63 cents per share, payable November 16, 2026, to shareholders of record at the close of business on October 15.
Risk Factors
- Abbott stock traded down 0.11 percent in after-hours trading on September 29, 2026, closing at EUR 88.67 versus a prior session close of EUR 88.77.
- The reference price for the session was EUR 88.77, with current quotes showing a bid of EUR 88.54 and an ask of EUR 88.80.
Full Analysis
Abbott Laboratories stock traded at EUR 88.67 in after-hours trading on September 29, 2026, representing a minor decline of 0.11 percent against the prior session's close of EUR 88.77. The reference price for the day was established at EUR 88.77, with current market quotes showing a bid of EUR 88.54 and an ask of EUR 88.80 on the Xetra exchange.
Earlier in the week, on September 27, Abbott announced significant positive data from clinical studies regarding its continuous glucose monitoring (CGM) technology for adults with Type 2 diabetes using basal insulin. The research involving nearly 28,000 participants indicated that CGM use was associated with a 45 percent lower risk of death at 12 months and a 36 percent lower risk at 24 months.
Additionally, a separate French observational study covering more than 253,000 people found that hospitalizations for acute diabetes events fell by 47 percent among users of Abbott's Libre technology who were on basal insulin. These findings highlight the clinical efficacy and potential market value of the company's core diabetes management solutions.
On September 17, Abbott's board declared a quarterly common dividend of 63 cents per share, payable to shareholders of record as of October 15, 2026, with payment scheduled for November 16. This dividend declaration reinforces the company's commitment to returning capital to investors while maintaining its focus on high-impact medical technologies.
